OBJECTIVE:To probe into the clinical efficacy of recombinant bovine basic fibroblast growth factor combined with sodium hyaluronate eye drops in treatment of xerophthalmia .METHODS: 90 patients xerophthalmia admitted into Hanchuan Prople’s Hospital from Feb.2014 to Nov.2015 were selected to be divided into observation group and control group via the number grouping method, with 45 cases in each.The control group were treated with sodium hyaluronate eye drops, while the observation group additionally received recombinant bovine basic fibroblast growth factor eye drops based on the control group.RESULTS:The total effective rate of observation group was 95.56%(43/45), significantly higher than that of control group 82.22%(37/45) , with statistically significant difference ( P<0.05) .After treatment , the tear breakup time of observation group was significantly higher than that of control group , yet SAI and SRI indicators were significantly lower than those of control group, with statistically significant difference (P <0.05).CONCLUSIONS: The efficacy of recombinant bovine basic fibroblast growth factor combined with sodium hyaluronate eye drops in treatment of xerophthalmia is remarkable with few adverse drug reactions and high safety .%目的：探讨重组牛碱性成纤维细胞生长因子滴眼液联合玻璃酸钠滴眼液治疗干眼病的临床疗效。方法：选取2014年2月—2015年11月汉川市人民医院收治的干眼病患者90例作为研究对象。采用单双号编号分组法分为观察组和对照组各45例。对照组患者给予玻璃酸钠滴眼液治疗，观察组患者在对照组的基础上，给予重组牛碱性成纤维细胞生长因子滴眼液治疗。结果：观察组患者总有效率为95．56％（43／45），显著高于对照组的82．22％（37／45），差异有统计学意义（P＜0．05）；治疗后，观察组患者的泪膜破裂时间明显高于对照组，角膜表面不对称指数、角膜表面规则指数指数明显低于对照组，差异均有统计学意义（ P＜0．05）。结论：重组牛碱性成纤维细胞生长因子滴眼液联合玻璃酸钠滴眼液治疗干眼病，疗效显著，无明显不良反应，安全性高。
展开▼
